One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
https://doi.org/10.1016/j.jval.2023.03.449
Copy DOI
Export
Save
Share
Cite Journal: Value in Health |  Publication Date: Jun 1, 2023 |
Affiliation: Hospital Del Mar, Merck (Germany), Hospital Universitario Lucus Augusti
We evaluated the cost-effectiveness of tepotinib vs. alternatives considered the standard of care in Spain in previously treated patients with advanced non-small-cell lung cancer harboring METex14 skipping alterations (aNSCLC METex14) from the payer perspective.
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
